company background image
AZT

ArcticZymes TechnologiesOB:AZT Stock Report

Market Cap

kr4.7b

7D

1.0%

1Y

64.9%

Updated

23 Sep, 2021

Data

Company Financials +
AZT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance5/6
Financial Health6/6
Dividends0/6

AZT Overview

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics (IVD), and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas.

Price History & Performance

Summary of all time highs, changes and price drops for ArcticZymes Technologies
Historical stock prices
Current Share Pricekr93.35
52 Week Highkr50.00
52 Week Lowkr114.40
Beta1.78
1 Month Change17.42%
3 Month Change6.08%
1 Year Change64.93%
3 Year Change1,805.10%
5 Year Change668.31%
Change since IPO273.40%

Recent News & Updates

Shareholder Returns

AZTNO BiotechsNO Market
7D1.0%0.8%0.5%
1Y64.9%45.5%25.9%

Return vs Industry: AZT exceeded the Norwegian Biotechs industry which returned 38.4% over the past year.

Return vs Market: AZT exceeded the Norwegian Market which returned 22.8% over the past year.

Price Volatility

Is AZT's price volatile compared to industry and market?
AZT volatility
AZT Beta1.78
Industry Beta1.4
Market Beta1

Stable Share Price: AZT is more volatile than 75% of Norwegian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: AZT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.

About the Company

FoundedEmployeesCEOWebsite
199031Jethro Holterhttps://arcticzymes.com

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics (IVD), and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020.

ArcticZymes Technologies Fundamentals Summary

How do ArcticZymes Technologies's earnings and revenue compare to its market cap?
AZT fundamental statistics
Market Capkr4.68b
Earnings (TTM)kr67.32m
Revenue (TTM)kr107.78m

69.6x

P/E Ratio

43.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AZT income statement (TTM)
Revenuekr107.78m
Cost of Revenuekr1.14m
Gross Profitkr106.64m
Expenseskr39.32m
Earningskr67.32m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Oct 28, 2021

Earnings per share (EPS)1.36
Gross Margin98.94%
Net Profit Margin62.47%
Debt/Equity Ratio0%

How did AZT perform over the long term?

See historical performance and comparison

Valuation

Is ArcticZymes Technologies undervalued compared to its fair value and its price relative to the market?

8.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AZT (NOK93.35) is trading below our estimate of fair value (NOK102.47)

Significantly Below Fair Value: AZT is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: AZT is poor value based on its PE Ratio (69.6x) compared to the European Biotechs industry average (24.9x).

PE vs Market: AZT is poor value based on its PE Ratio (69.6x) compared to the Norwegian market (13.2x).


Price to Earnings Growth Ratio

PEG Ratio: AZT is poor value based on its PEG Ratio (3.9x)


Price to Book Ratio

PB vs Industry: AZT is overvalued based on its PB Ratio (21.3x) compared to the NO Biotechs industry average (3.9x).


Future Growth

How is ArcticZymes Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

17.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AZT's forecast earnings growth (17.7% per year) is above the savings rate (1.2%).

Earnings vs Market: AZT's earnings (17.7% per year) are forecast to grow faster than the Norwegian market (10.1% per year).

High Growth Earnings: AZT's earnings are forecast to grow, but not significantly.

Revenue vs Market: AZT's revenue (25.8% per year) is forecast to grow faster than the Norwegian market (5.7% per year).

High Growth Revenue: AZT's revenue (25.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AZT's Return on Equity is forecast to be high in 3 years time (24.7%)


Past Performance

How has ArcticZymes Technologies performed over the past 5 years?

69.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AZT has a high level of non-cash earnings.

Growing Profit Margin: AZT's current net profit margins (62.5%) are higher than last year (54.1%).


Past Earnings Growth Analysis

Earnings Trend: AZT has become profitable over the past 5 years, growing earnings by 69% per year.

Accelerating Growth: AZT's earnings growth over the past year (83.6%) exceeds its 5-year average (69% per year).

Earnings vs Industry: AZT earnings growth over the past year (83.6%) exceeded the Biotechs industry 19.9%.


Return on Equity

High ROE: AZT's Return on Equity (31.4%) is considered high.


Financial Health

How is ArcticZymes Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: AZT's short term assets (NOK201.0M) exceed its short term liabilities (NOK13.5M).

Long Term Liabilities: AZT's short term assets (NOK201.0M) exceed its long term liabilities (NOK17.6M).


Debt to Equity History and Analysis

Debt Level: AZT is debt free.

Reducing Debt: AZT has not had any debt for past 5 years.

Debt Coverage: AZT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AZT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is ArcticZymes Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AZT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AZT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AZT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AZT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AZT's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Jethro Holter (49 yo)

1.92yrs

Tenure

kr1,903,000

Compensation

Dr. Jethro Holter has been Chief Executive Officer of ArcticZymes Technologies ASA (formerly known as Biotec Pharmacon ASA) since April 22, 2020. He was an Interim CEO at Biotec Pharmacon ASA since October...


CEO Compensation Analysis

Compensation vs Market: Jethro's total compensation ($USD221.82K) is below average for companies of similar size in the Norwegian market ($USD616.98K).

Compensation vs Earnings: Jethro's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: AZT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: AZT's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.


Top Shareholders

Company Information

ArcticZymes Technologies ASA's employee growth, exchange listings and data sources


Key Information

  • Name: ArcticZymes Technologies ASA
  • Ticker: AZT
  • Exchange: OB
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr4.683b
  • Shares outstanding: 50.17m
  • Website: https://arcticzymes.com

Number of Employees


Location

  • ArcticZymes Technologies ASA
  • Sykehusveien 23
  • PO Box 6463
  • Tromsø
  • Troms
  • 9294
  • Norway

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 21:39
End of Day Share Price2021/09/23 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.